| PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase YL Kwong, TSY Chan, D Tan, SJ Kim, LM Poon, B Mow, PL Khong, ... Blood, The Journal of the American Society of Hematology 129 (17), 2437-2442, 2017 | 497 | 2017 |
| SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group YL Kwong, WS Kim, ST Lim, SJ Kim, T Tang, E Tse, AYH Leung, CS Chim Blood, The Journal of the American Society of Hematology 120 (15), 2973-2980, 2012 | 450 | 2012 |
| Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium … SJ Kim, K Kim, BS Kim, CY Kim, C Suh, J Huh, SW Lee, JS Kim, J Cho, ... Journal of clinical oncology 27 (35), 6027-6032, 2009 | 400 | 2009 |
| A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma HY Yoo, MK Sung, SH Lee, S Kim, H Lee, S Park, SC Kim, B Lee, K Rho, ... Nature genetics 46 (4), 371-375, 2014 | 395 | 2014 |
| A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis SJ Kim, DH Yoon, A Jaccard, WJ Chng, ST Lim, H Hong, Y Park, ... The lancet oncology 17 (3), 389-400, 2016 | 357 | 2016 |
| Expression of HIF-1α, CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung cancer SJ Kim, ZN Rabbani, MW Dewhirst, Z Vujaskovic, RT Vollmer, ... Lung cancer 49 (3), 325-335, 2005 | 250 | 2005 |
| Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma K Ohmachi, N Niitsu, T Uchida, SJ Kim, K Ando, N Takahashi, ... Journal of clinical oncology 31 (17), 2103-2109, 2013 | 205 | 2013 |
| Cilta-cel or standard care in lenalidomide-refractory multiple myeloma J San-Miguel, B Dhakal, K Yong, A Spencer, S Anguille, MV Mateos, ... New England Journal of Medicine 389 (4), 335-347, 2023 | 189 | 2023 |
| Type II enteropathy‐associated T‐cell lymphoma: a multicenter analysis from the Asia Lymphoma Study Group E Tse, H Gill, F Loong, SJ Kim, SB Ng, T Tang, YH Ko, WJ Chng, ST Lim, ... American journal of hematology 87 (7), 663-668, 2012 | 173 | 2012 |
| Genetic alterations of JAK/STAT cascade and histone modification in extranodal NK/T-cell lymphoma nasal type S Lee, HY Park, SY Kang, SJ Kim, J Hwang, S Lee, SH Kwak, KS Park, ... Oncotarget 6 (19), 17764, 2015 | 160 | 2015 |
| Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group SJ Kim, C Hsu, YQ Song, K Tay, XN Hong, J Cao, JS Kim, HS Eom, ... European journal of cancer 49 (16), 3486-3496, 2013 | 150 | 2013 |
| Comparison of treatment strategies for patients with intestinal diffuse large B-cell lymphoma: surgical resection followed by chemotherapy versus chemotherapy alone SJ Kim, HJ Kang, JS Kim, SY Oh, CW Choi, SI Lee, JH Won, MK Kim, ... Blood, The Journal of the American Society of Hematology 117 (6), 1958-1965, 2011 | 148 | 2011 |
| Multicenter retrospective analysis of 581 patients with primary intestinal non-hodgkin lymphoma from the Consortium for Improving Survival of Lymphoma (CISL) SJ Kim, CW Choi, YC Mun, SY Oh, HJ Kang, SI Lee, JH Won, MK Kim, ... BMC cancer 11, 1-12, 2011 | 145 | 2011 |
| Ki-67 expression is predictive of prognosis in patients with stage I/II extranodal NK/T-cell lymphoma, nasal type SJ Kim, BS Kim, CW Choi, J Choi, I Kim, YH Lee, JS Kim Annals of oncology 18 (8), 1382-1387, 2007 | 144 | 2007 |
| Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial SJ Kim, DH Yoon, HJ Kang, JS Kim, SK Park, HJ Kim, J Lee, BY Ryoo, ... European journal of cancer 48 (17), 3223-3231, 2012 | 136 | 2012 |
| Concurrent chemoradiotherapy followed by l-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK/T cell lymphoma: CISL08-01 phase II … SJ Kim, DH Yang, JS Kim, JY Kwak, HS Eom, DS Hong, JH Won, JH Lee, ... Annals of hematology 93, 1895-1901, 2014 | 130 | 2014 |
| Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL) YR Kim, JS Kim, YH Min, DH Yoon, HJ Shin, YC Mun, Y Park, YR Do, ... Journal of Hematology & Oncology 5, 1-9, 2012 | 118 | 2012 |
| Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell Project CP Fox, M Civallero, YH Ko, M Manni, T Skrypets, S Pileri, SJ Kim, ... The Lancet Haematology 7 (4), e284-e294, 2020 | 117 | 2020 |
| Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study SJ Kim, JW Lee, CW Jung, CK Min, B Cho, HJ Shin, JS Chung, H Kim, ... haematologica 95 (11), 1935, 2010 | 116 | 2010 |
| Carbonic Anhydrase IX in Early-Stage Non–Small Cell Lung Cancer SJ Kim, ZN Rabbani, RT Vollmer, EG Schreiber, E Oosterwijk, ... Clinical cancer research 10 (23), 7925-7933, 2004 | 115 | 2004 |
Won Seog kimSamsung Medical Center在 skku.edu 的电子邮件经过验证
Won Seog kimSamsung Medical Center在 skku.edu 的电子邮件经过验证